GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (XSWX:GALD) » Definitions » Intrinsic Value: Projected FCF

Galderma Group AG (XSWX:GALD) Intrinsic Value: Projected FCF : CHF0.00 (As of Nov. 14, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-11-14), Galderma Group AG's Intrinsic Value: Projected FCF is CHF0.00. The stock price of Galderma Group AG is CHF84.75. Therefore, Galderma Group AG's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Galderma Group AG's Intrinsic Value: Projected FCF or its related term are showing as below:

XSWX:GALD's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.74
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Galderma Group AG Intrinsic Value: Projected FCF Historical Data

The historical data trend for Galderma Group AG's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Intrinsic Value: Projected FCF Chart

Galderma Group AG Annual Data
Trend
Intrinsic Value: Projected FCF

Galderma Group AG Semi-Annual Data
Jun23 Jun24
Intrinsic Value: Projected FCF - -

Competitive Comparison of Galderma Group AG's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galderma Group AG's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Galderma Group AG's Price-to-Projected-FCF falls into.



Galderma Group AG Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Galderma Group AG  (XSWX:GALD) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Galderma Group AG's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=84.75/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galderma Group AG Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Galderma Group AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines